Paper24201212
Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy.
Flotte TR. Mol Ther, 2013. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy. Papers, record 24201212. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24201212
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Dependovirus | Major topic |
| Genetic Therapy | Major topic |
| Genetic Vectors | Major topic |
| Clinical Trials as Topic | |
| Evolution, Molecular | |
| History, 20th Century | |
| History, 21st Century | |
| Humans | |
| National Institutes of Health (U.S.) | |
| Phylogeny | |
| United States |
Source PubMed
References100
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19953081 | Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. | Mol Ther | 2010 | https://conductscience.org/library/papers/19953081 | PubMed |
| 2 | 16076250 | Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy. | Hum Gene Ther | 2005 | https://conductscience.org/library/papers/16076250 | PubMed |
| 3 | 12954205 | Characterization of the adenoassociated virus Rep protein complex formed on the viral origin of DNA replication. | Virology | 2003 | https://conductscience.org/library/papers/12954205 | PubMed |
| 4 | 17115945 | Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. | Hum Gene Ther | 2006 | https://conductscience.org/library/papers/17115945 | PubMed |
| 5 | 14769732 | Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. | Chest | 2004 | https://conductscience.org/library/papers/14769732 | PubMed |
| 6 | 9581911 | A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. | Hum Gene Ther | 1998 | https://conductscience.org/library/papers/9581911 | PubMed |
| 7 | 20606642 | A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. | Mol Ther | 2010 | https://conductscience.org/library/papers/20606642 | PubMed |
| 8 | 8773517 | A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. | Hum Gene Ther | 1996 | https://conductscience.org/library/papers/8773517 | PubMed |
| 9 | 14325163 | ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES. | Science | 1965 | https://conductscience.org/library/papers/14325163 | PubMed |
| 10 | 8151765 | Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels. | J Virol | 1994 | https://conductscience.org/library/papers/8151765 | PubMed |
| 11 | 12162817 | A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. | Hum Gene Ther | 2002 | https://conductscience.org/library/papers/12162817 | PubMed |
| 12 | 7946381 | Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. | Am J Respir Cell Mol Biol | 1994 | https://conductscience.org/library/papers/7946381 | PubMed |
| 13 | 2153052 | In vitro resolution of covalently joined AAV chromosome ends. | Cell | 1990 | https://conductscience.org/library/papers/2153052 | PubMed |
| 14 | 11263951 | Adeno-associated virus is associated with a lower risk of high-grade cervical neoplasia. | Exp Mol Pathol | 2001 | https://conductscience.org/library/papers/11263951 | PubMed |
| 15 | 19854499 | Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. | Lancet | 2009 | https://conductscience.org/library/papers/19854499 | PubMed |
| 16 | 14965381 | Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. | Hum Gene Ther | 2004 | https://conductscience.org/library/papers/14965381 | PubMed |
| 17 | 6095038 | A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase. | Mol Cell Biol | 1984 | https://conductscience.org/library/papers/6095038 | PubMed |
| 18 | 8627804 | In vivo model of adeno-associated virus vector persistence and rescue. | J Virol | 1996 | https://conductscience.org/library/papers/8627804 | PubMed |
| 19 | 10196295 | Gene therapy vectors based on adeno-associated virus type 1. | J Virol | 1999 | https://conductscience.org/library/papers/10196295 | PubMed |
| 20 | 12716974 | Adeno-associated viruses undergo substantial evolution in primates during natural infections. | Proc Natl Acad Sci U S A | 2003 | https://conductscience.org/library/papers/12716974 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42278347 | Safety of Adeno-Associated Viral Vectors in Gene Therapy: Mechanisms of Toxicity, Clinical Risks, and Strategies for Their Minimization. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278347 | PubMed |
| 41257285 | Transcriptional changes in non-human primate tissues after intrathecal delivery of serotype 9 adeno-associated viral vector: Insights into organ toxicities. | Mol Ther Methods Clin Dev | 2025 | https://conductscience.org/library/papers/41257285 | PubMed |
| 41179895 | AAV viral vectors as therapeutic interventions for inherited or non-inherited cardiac disorders: current aspects and future prospects. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41179895 | PubMed |
| 40186350 | AAV vector development, back to the future. | Mol Ther | 2025 | https://conductscience.org/library/papers/40186350 | PubMed |
| 39225214 | Recent Advances in Therapeutics and Manufacturing Processes of Recombinant Adeno-Associated Virus for the Treatment of Lung Diseases. | Curr Gene Ther | 2025 | https://conductscience.org/library/papers/39225214 | PubMed |
| 37310260 | Structural and Biophysical Analysis of Adeno-Associated Virus Serotype 2 Capsid Assembly Variants. | J Virol | 2023 | https://conductscience.org/library/papers/37310260 | PubMed |
| 36986717 | Gene Therapy for Regenerative Medicine. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/36986717 | PubMed |
| 35297680 | Development of a Beta Cell-Specific Expression Control Element for Recombinant Adeno-Associated Virus. | Hum Gene Ther | 2022 | https://conductscience.org/library/papers/35297680 | PubMed |
| 35283274 | Durability of transgene expression after rAAV gene therapy. | Mol Ther | 2022 | https://conductscience.org/library/papers/35283274 | PubMed |
| 34522582 | In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges. | Acta Pharm Sin B | 2021 | https://conductscience.org/library/papers/34522582 | PubMed |
| 28944281 | Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine. | Genes Dis | 2017 | https://conductscience.org/library/papers/28944281 | PubMed |
| 28774883 | The cardiac microenvironment uses non-canonical WNT signaling to activate monocytes after myocardial infarction. | EMBO Mol Med | 2017 | https://conductscience.org/library/papers/28774883 | PubMed |
| 28142241 | Probing the Link among Genomic Cargo, Contact Mechanics, and Nanoindentation in Recombinant Adeno-Associated Virus 2. | J Phys Chem B | 2017 | https://conductscience.org/library/papers/28142241 | PubMed |
| 27434683 | CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector. | Mol Ther Nucleic Acids | 2016 | https://conductscience.org/library/papers/27434683 | PubMed |
| 27362483 | CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent Infections. | PLoS Pathog | 2016 | https://conductscience.org/library/papers/27362483 | PubMed |
| 26305933 | Genome-wide RNAi screening identifies host restriction factors critical for in vivo AAV transduction. | Proc Natl Acad Sci U S A | 2015 | https://conductscience.org/library/papers/26305933 | PubMed |
| 25091489 | State-of-the-art human gene therapy: part I. Gene delivery technologies. | Discov Med | 2014 | https://conductscience.org/library/papers/25091489 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24201212
GET https://conductscience.org/api/papers/v1/24201212/references?page=2